<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03923270</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19942</org_study_id>
    <nct_id>NCT03923270</nct_id>
  </id_info>
  <brief_title>Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer</brief_title>
  <official_title>Sequential Maintenance With Thoracic Radiotherapy and Durvalumab (MEDI4736) Monotherapy or Durvalumab (MEDI 4736) Combinations (Tremelimumab or Olaparib) in Patients With Extensive Stage-Small Cell Lung Cancer After First Line Platinum Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation&#xD;
      therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or&#xD;
      olaparib in participants with Extensive-Stage Disease Small Cell Lung Cancer (ES-SCLC) who&#xD;
      have completed a first-line platinum-based chemotherapy regimen and achieved ongoing complete&#xD;
      response (CR), partial response (PR) or stable disease (SD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Unacceptable Serious Adverse Events (SAEs)</measure>
    <time_frame>13 weeks</time_frame>
    <description>Unacceptable toxicity status at the end of 13-week safety observation period with unacceptable toxicity defined as:&#xD;
Any grade 4 immune related adverse event (irAE),&#xD;
Any ≥ grade 3 noninfectious pneumonitis,&#xD;
Any ≥ grade 3 colitis,&#xD;
Any grade 3 irAE, excluding colitis or pneumonitis, that does not downgrade to grade 2 within 7 days after onset of the event despite optimal medical management including systemic corticosteroids or does not downgrade to ≤ grade 1 or baseline within 14 days,&#xD;
Liver transaminase elevation &gt; 8 × Upper Limit of Normal (ULN) or total bilirubin &gt; 5 × ULN&#xD;
Any ≥ grade 3 non-irAE with exceptions per protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase IB: Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Progression Free Survival (PFS) defined as the duration from date of registration to date of first documentation of progression assessed by local investigator or symptomatic deterioration or death due to any cause. Patients last known to be alive are censored at date of last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Progression Free Survival (PFS) is defined as the duration from date of registration to date of first documentation of progression assessed by local investigator or symptomatic deterioration (as defined above) or death due to any cause. Patients last known to be alive are censored at date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Overall Survival (OS) will is defined as the duration from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Small Cell Lung Cancer Extensive Stage</condition>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This Arm is a standard of care Arm. Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 13 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks for up to 4 doses and 75mg intravenously of Tremelimumab every 4 weeks for up to 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and Olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg orally of Olaparib twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive thoracic radiotherapy (30 Gray units total, 3 Gray units X 10 fractions), then in 2-3 weeks begin 1500 mg intravenously of Durvalumab every 4 weeks and 300 mg Tremelimumab IV x 1 (single dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.</description>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab</arm_group_label>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab</arm_group_label>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and Olaparib</arm_group_label>
    <other_name>Imfinzi</other_name>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.</description>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib Pill</intervention_name>
    <description>Participants in arm C will be self-administer 300 mg of Olaparib orally.</description>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and Olaparib</arm_group_label>
    <other_name>Lynparza</other_name>
    <other_name>MK-7339</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic Radiotherapy</intervention_name>
    <description>Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions</description>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab</arm_group_label>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 75mg Tremelimumab</arm_group_label>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and Olaparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose</description>
    <arm_group_label>Thoracic Radiotherapy plus Durvalumab and 300mg Tremelimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Body weight greater than 30 kg&#xD;
&#xD;
          -  Participants must be willing and able to comply with scheduled visits, treatment&#xD;
             schedule, laboratory tests and other requirements of the study.&#xD;
&#xD;
          -  Participants must have small cell lung cancer, documented by histology or cytology&#xD;
             from brushing, washing, fine needle aspiration or core biopsy from a defined lesion,&#xD;
             but not from sputum cytology alone. No mixed histologies allowed.&#xD;
&#xD;
          -  Participants must be presented at initial diagnosis with extensive-stage disease&#xD;
             (ES-SCLC).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1.&#xD;
&#xD;
          -  Participants must have received 4-6 cycles of platinum-based first-line chemotherapy&#xD;
             and must have an ongoing complete response (CR), partial response (PR), or stable&#xD;
             disease (SD) after completion. Acceptable combinations (NCCN guidelines), include&#xD;
             cisplatin or carboplatin with etoposide or irinotecan. As an exception to the above&#xD;
             criterion, participants receiving only 3 cycles of chemotherapy due to toxicity are&#xD;
             eligible, if they have an ongoing PR or CR after the 3rd cycle. Participants who have&#xD;
             received &gt; 6 cycles of platinum-based first-line chemotherapy are not eligible.&#xD;
             Participants receiving checkpoint inhibitor (CPI) monotherapy (anti-PD-1, anti-PD-L1,&#xD;
             others) as part of their first line chemotherapy treatment will be eligible as long as&#xD;
             they discontinue the CPI prior to the start of thoracic radiotherapy.&#xD;
&#xD;
          -  Participants must initiate study treatment with thoracic XRT ≤ 60 days from the last&#xD;
             dose of platinum- based first line chemotherapy;&#xD;
&#xD;
          -  Whenever possible, a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or&#xD;
             5-10 unstained slides of tumor sample (archival) should be made available (less&#xD;
             material is acceptable);&#xD;
&#xD;
          -  Participants must have a life expectancy of 16 weeks or more.&#xD;
&#xD;
          -  Active infection including: tuberculosis, hepatitis B (known positive hepatitis B&#xD;
             surface antigen (HBsAg) result) and/or, hepatitis C. Patients with a past or resolved&#xD;
             hepatitis B infection (defined as the presence of hepatitis B core antibody [anti-HBc]&#xD;
             and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody&#xD;
             are eligible only if polymerase chain reaction is negative for HCV RNA (indicating no&#xD;
             current infection).&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus (positive HIV 1/2 antibodies) or&#xD;
             known medical history of acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Adequate bone marrow function measured within 28 days prior to administration of study&#xD;
             as defined per protocol.&#xD;
&#xD;
          -  Adequate rental function as defined per protocol.&#xD;
&#xD;
          -  Adequate hepatic function as defined per protocol&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) patients or male patients who are sexually&#xD;
             active with WOCBP and female partners of male participants must agree to follow&#xD;
             instructions of &quot;highly effective methods of contraception) per protocol for duration&#xD;
             of treatment with study drug(s) plus the specified washout period.&#xD;
&#xD;
          -  Male participants must be willing to refrain from sperm donation during the study and&#xD;
             for at least 180 days after the last dose of durvalumab combination therapy, 90 days&#xD;
             after the last dose of durvalumab or olaparib monotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with previous brain metastases are eligible provided that they are&#xD;
             treated, are asymptomatic, and have stable disease at the screening tumor assessment.&#xD;
             A ≥ 2 week disease stable interval as confirmed by MRI or CT brain w/ contrast (Table&#xD;
             7.4-2) is required after treatment of brain metastases before initiation of thoracic&#xD;
             XRT. In addition, subjects must have been either off corticosteroids, or on a stable&#xD;
             or decreasing dose of ≤10 mg daily prednisone (or equivalent).&#xD;
&#xD;
          -  Participants who have received prior thoracic XRT are excluded.&#xD;
&#xD;
          -  Participants with Carcinomatous meningitis&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             Wegener syndrome and hypophysitis or uveitis. Patients with an autoimmune&#xD;
             paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded.&#xD;
             Patients with type I diabetes mellitus, hypothyroidism only requiring hormone&#xD;
             replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring&#xD;
             systemic treatment, or conditions not expected to recur in the absence of an external&#xD;
             trigger are permitted to enroll&#xD;
&#xD;
          -  Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt; 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of study treatment (excluding thoracic radiotherapy). Some exceptions apply.&#xD;
&#xD;
          -  Prior CPI therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4&#xD;
             antibody (including any other antibody or drug specifically targeting T cell&#xD;
             co-stimulation or checkpoint pathways). Exception: CPI use with first line&#xD;
             chemotherapy that is stopped prior to trial enrollment.&#xD;
&#xD;
          -  Participants who have received any previous treatment with a Poly ADP Ribose&#xD;
             Polymerase (PARP) inhibitor, including olaparib&#xD;
&#xD;
          -  Interstitial lung disease (ILD): Any evidence of current ILD or pneumonitis or a prior&#xD;
             history of ILD or pneumonitis requiring oral or IV glucocorticoids.&#xD;
&#xD;
          -  Previous malignancies unless a complete control (no evidence of disease) was achieved&#xD;
             ≥ 2 years prior to study entry AND no additional therapy is required during the study&#xD;
             period (EXCEPT: adequately treated non-melanoma skin cancer, curatively treated in&#xD;
             situ cancer and stage 1, grade 1 endometrial cancer).&#xD;
&#xD;
          -  Participants with a known medical condition that, in the investigator's opinion, would&#xD;
             increase the risk associated with study participation or study drug(s) administration&#xD;
             or interfere with the interpretation of safety results.&#xD;
&#xD;
          -  Major surgery or significant traumatic injury that is not recovered at least 14 days&#xD;
             before the initiation of thoracic radiation therapy&#xD;
&#xD;
          -  All toxicities attributed to prior anti-cancer therapy must have been resolved to&#xD;
             Grade 1 (NCI CTCAE Version 5.0) or baseline before administration of study drug(s).&#xD;
             Some exceptions apply.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients.&#xD;
&#xD;
          -  Patients with known contraindications to radiotherapy, including inherited syndromes&#xD;
             associated with hypersensitivity to ionizing radiation (e.g., Ataxia-Telangiectasia,&#xD;
             Nijmegen Breakage Syndrome).&#xD;
&#xD;
          -  History of allergy or hypersensitivity to any of the study drugs or study drug&#xD;
             components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto A Chiappori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Ackerman</last_name>
      <phone>813-745-7363</phone>
      <email>Tara.Ackerman@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Lazic</last_name>
      <phone>813-745-1480</phone>
      <email>Kristina.Lazic@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto A Chiappori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ben C Creelan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Dilling, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jhanelle E Gray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric B Haura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradford Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Rosenberg, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Saltos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael R Shafique, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanee C Smikker, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tawee Tanvetyanon, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam H Vafadar, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://moffitt.org/clinical-trials-research/clinical-trials/</url>
    <description>Moffitt Cancer Center Clinical Trials Website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

